-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FPvoKayJ6A5+jmWJBiZmEVWrn84B/7TzEXP+jYewVwsvw6Ray46rrw246tZ4LZjc r/L9l+nnPyn6DGKALBaWvw== 0001193125-04-018453.txt : 20040210 0001193125-04-018453.hdr.sgml : 20040210 20040210170715 ACCESSION NUMBER: 0001193125-04-018453 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20040210 GROUP MEMBERS: ATLAS INVESTERINGSGROEP N.V. GROUP MEMBERS: ATLAS VENTURE ASSOCIATES II, L.P. GROUP MEMBERS: ATLAS VENTURE EUROPE FUND B.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: DECODE GENETICS INC CENTRAL INDEX KEY: 0001022974 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043326704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-59361 FILM NUMBER: 04582806 BUSINESS ADDRESS: STREET 1: 8 STURLUGATA STREET 2: IS 101 CITY: REYJKAVIK STATE: K6 ZIP: 00000 BUSINESS PHONE: 011 354 570 1900 MAIL ADDRESS: STREET 1: 8 STURLUGATA STREET 2: IS 101 CITY: REYKJAVIK STATE: K6 ZIP: 00000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ATLAS VENTURE FUND II L P CENTRAL INDEX KEY: 0001030571 IRS NUMBER: 043226975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: C/O ATLAS VENTURE STREET 2: 222 BERKELEY STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6178599290 MAIL ADDRESS: STREET 1: C/O ATLAS VENTURE STREET 2: 222 BERKELEY STREET CITY: BOSTON STATE: MA ZIP: 02116 SC 13G/A 1 dsc13ga.htm SCHEDULE 13G/A SCHEDULE 13G/A
CUSIP No. 243586104   13G   Page 1 of 6 Pages

 

OMB APPROVAL

OMB Number:

    3235-0145

Expires:

    December 31, 2005

Estimated average burden

hours per response . . . 11

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

 

 

 

deCODE genetics, Inc.

(Name of Issuer)

 

 

COMMON STOCK, $.001 par value

(Title of Class of Securities)

 

 

243586104

                                (CUSIP Number)                                

 

 

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

¨ Rule 13d-1(c)

 

x Rule 13d-1(d)

 

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 243586104   13G   Page 2 of 6 Pages

 

Schedule 13G

 

 

Item 1.

  

(a)

    Name of Issuer:
         deCODE genetics, Inc.
   

(b)

   

Address of Issuer’s Principal Executive Offices:

        

Sturlugata 8, IS-101, Reykjavik, Iceland.

Item 2.

  

(a)

    Name of Person Filing:
         Atlas Venture Fund II, L.P., Atlas Venture Associates II, L.P., Atlas Venture Europe Fund B.V. and Atlas InvesteringsGroep N.V.
         Atlas Venture Associates II, L.P. is the sole general partner of Atlas Venture Fund II, L.P. Atlas InvesteringsGroep N.V. is the owner of 95% of the shares of Atlas Venture Europe Fund B.V.
   

(b)

    Address of Principal Business Office or, if none, Residence:
         The address of the principal business office of Atlas Venture Fund II, L.P. and Atlas Venture Associates II, L.P. is Atlas Venture, 890 Winter Street, Suite 320, Waltham, Massachusetts 02451. The address of the principal business office of Atlas Venture Europe Fund B.V. and Atlas InvesteringsGroep N.V. is Atlas InvesteringsGroep N.V., Bachlaan 37, 1217 BV Hilversum, The Netherlands.
   

(c)

    Citizenship:
         Atlas Venture Fund II, L.P. and Atlas Venture Associates II, L.P. are each a limited partnership organized under the laws of the State of Delaware. Atlas Venture Europe Fund B.V. and Atlas InvesteringsGroep N.V. are each a corporation organized under the laws of The Netherlands.
   

(d)

   

Title of Class of Securities:

        

Common Stock, $.001 par value.

   

(e)

   

CUSIP Number:

        

243586104.

Item 3.

  

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:

    Not Applicable.

Item 4.

  

Ownership.

          
   

Not Applicable.

     

Item 5.

  

Ownership of Five Percent or Less of a Class

          
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
    x Atlas Venture Fund II, L.P., Atlas Venture Associates II, L.P., Atlas Venture Europe Fund B.V. and Atlas InvesteringsGroep N.V. are each deemed to own less than five percent of outstanding shares of common stock of deCODE genetics, Inc. as of December 31, 2003.

Item 6.

  

Ownership of More than Five Percent on Behalf of Another Person.

          
   

Not Applicable.

     

Item 7.

   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
    Not Applicable.     

CUSIP No. 243586104   13G   Page 3 of 6 Pages

Item 8.

    Identification and Classification of Members of the Group          
    

Not Applicable. The reporting persons expressly disclaim membership in a “group” as defined in Rule

13d-1(b)(1)(ii)(J).

Item 9.

    Notice of Dissolution of Group          
     Not Applicable.          

Item 10.

    Certification          
     Not Applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d-1(c).          

CUSIP No. 243586104   13G   Page 4 of 6 Pages

 

Signatures

 

After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement filed herewith as Exhibit 1.

 

Dated: February 10, 2004

 

ATLAS VENTURE FUND II, L.P.

      

ATLAS VENTURE EUROPE FUND B.V.

By:   Atlas Venture Associates II, L.P. General Partner       By:   Atlas InvesteringsGroep N.V.
    By:  

*

           By:  

*

       

Christopher J. Spray,

General Partner

              

Hans Bosman,

Managing Director

 

ATLAS VENTURE ASSOCIATES II, L.P.

      

ATLAS INVESTERINGSGROEP N.V.

By:   *             By:   *    
   
         
   

Christopher J. Spray,

General Partner

          

Hans Bosman,

Managing Director

 

* The undersigned attorney-in-fact, by signing her name below, does hereby sign this statement on behalf of the above indicated filers pursuant to Power of Attorney filed herewith as Exhibit 2.

 

/s/    Jeanne Larkin Henry   

Jeanne Larkin Henry

Attorney-in-fact

CUSIP No. 243586104   13G   Page 5 of 6 Pages

 

INDEX TO EXHIBITS

 

Exhibit

Number

   

Description

    Page
1    Agreement pursuant to Rule 13d-1(k)(1)    6
2    Power of Attorney (*)     
(*) Incorporated by reference to Schedule 13G for deCODE genetics, Inc. filed with the Securities and Exchange Commission on February 14, 2001 by Atlas Venture Fund II, L.P., Atlas Venture Associates II, L.P., Atlas Venture Europe Fund B.V. and Atlas InvsteringsGroep N.V.

 

 EX-1 3 dex1.htm AGREEMENT PURSUANT TO RULE 13D-1(K)(1) AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

Exhibit 1

 

AGREEMENT

 

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of deCODE genetics, Inc.

 

This agreement may be executed in any number of counterparts, each of which shall be deemed an original.

 

EXECUTED this 10 day of February, 2004.

 

ATLAS VENTURE FUND II, L.P.

      

ATLAS VENTURE EUROPE FUND B.V.

By:

  

Atlas Venture Associates II, L.P.

      

By:

  

Atlas InvesteringsGroep N.V.

   

By:

  

*

          

By:

  

*

        Christopher J. Spray,               Hans Bosman,
        General Partner               Managing Director

ATLAS VENTURE ASSOCIATES II, L.P.

      

ATLAS INVESTERINGSGROEP N.V.

By:

  

*

      

By:

  

*

    Christopher J. Spray,           Hans Bosman,
    General Partner           Managing Director

 

* The undersigned attorney-in-fact, by signing her name below, does hereby sign this statement on behalf of the above indicated filers pursuant to Power of Attorney filed herewith as Exhibit 2.

 

/s/    Jeanne Larkin Henry        

Jeanne Larkin Henry
Attorney-in-fact
 -----END PRIVACY-ENHANCED MESSAGE-----